Brazil Pharma and Healthcare Sector 2024-2025

Brazil's pharmaceutical and healthcare sector is navigating the post-pandemic period with some positives but also quite a few challenges. Among the positives is a sharp rise in public health spending observed in 2021-2023 compared to the pre-pandemic period, despite significant volatility in federal healthcare expenditure due to changing budgetary rules. Moreover, private healthcare is expanding in new markets (e.g., pet insurance) and through new channels (such as retail loyalty programmes). However, a double-edged sword for the sector is the rapid rise in the medical workforce, particularly in 2023, as the overall amount of health professionals is solid but poorly distributed in geographical terms, and there are concerns about declining quality in healthcare education. The domestic pharmaceutical manufacturing segment, although quite well developed by Latin American standards, is broadly specialised in generics and cannot compete with foreign players in high-cost drugs, leading to increasing external trade imbalances in pharmaceuticals.

This report provides a complete and detailed analysis of the "Pharmaceuticals production" sector for Brazil. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Pharmaceuticals production" sector in Brazil
• Crystallise the forces both driving and restraining this sector in Brazil
• Ascertain Brazil’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Brazil.
• Build a clear picture of trends, output and consumption for specific sub-sectors